Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1464	60166-93-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iopamidol iopamiron	A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures. Molecular weight: 777.09 Formula: C17H22I3N3O8 CLOGP: -1.91 LIPINSKI: 3 HAC: 11 HDO: 8 TPSA: 188.45 ALOGS: -2.99 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iopamidol
iopamiron

A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.

Molecular weight: 777.09
Formula: C17H22I3N3O8
CLOGP: -1.91
LIPINSKI: 3
HAC: 11
HDO: 8
TPSA: 188.45
ALOGS: -2.99
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	96 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1530.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.28 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.10 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	49
kinase-selectivity-class	ALK,AURKA,AURKC,AXL,BMX,BRAF,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3A,GSK3B,IRAK3,MAP2K6,MAP3K21,MAP4K1,MAPK1,MAPK11,MAPK7,MET,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1	45
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1985	FDA	BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	338.11	28.00	56	3538	1195	90623658
Anaphylactic reaction	200.97	28.00	88	3506	87436	90537417
Anaphylactic shock	158.43	28.00	56	3538	31561	90593292
Contrast encephalopathy	154.21	28.00	22	3572	163	90624690
Urticaria	97.64	28.00	88	3506	312646	90312207
No adverse event	96.10	28.00	49	3545	67933	90556920
Drug reaction with eosinophilia and systemic symptoms	88.33	28.00	40	3554	42718	90582135
Contrast media allergy	77.06	28.00	19	3575	3062	90621791
Throat tightness	75.20	28.00	32	3562	29452	90595401
Sneezing	74.80	28.00	32	3562	29837	90595016
Extravasation	72.73	28.00	18	3576	2946	90621907
Sialoadenitis	62.45	28.00	15	3579	2167	90622686
Anaphylactoid reaction	60.80	28.00	17	3577	4451	90620402
Cardio-respiratory arrest	57.33	28.00	34	3560	63106	90561747
Dyspnoea	51.90	28.00	110	3484	880845	89744008
Wrong product administered	51.75	28.00	17	3577	7648	90617205
Throat irritation	48.90	28.00	28	3566	48667	90576186
Maternal exposure during pregnancy	43.64	28.00	62	3532	360001	90264852
Hypersensitivity	42.00	28.00	69	3525	454608	90170245
Pulse absent	39.15	28.00	13	3581	6042	90618811
Respiratory arrest	38.46	28.00	21	3573	33290	90591563
Infusion site extravasation	35.88	28.00	14	3580	10314	90614539
Unresponsive to stimuli	35.82	28.00	21	3573	38100	90586753
Cardiac arrest	35.52	28.00	31	3563	104904	90519949
Erythema	34.65	28.00	44	3550	229202	90395651
Pruritus	32.16	28.00	68	3526	541457	90083396
Product physical issue	32.05	28.00	11	3583	5649	90619204
Pharyngeal oedema	31.99	28.00	14	3580	13757	90611096
Blood pressure decreased	29.18	28.00	24	3570	74871	90549982
Rapidly progressive osteoarthritis	28.62	28.00	4	3590	25	90624828

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	285.37	24.75	52	3001	1064	42617218
Anaphylactic shock	259.05	24.75	87	2966	23430	42594852
Anaphylactic reaction	178.53	24.75	78	2975	42665	42575617
Contrast encephalopathy	150.74	24.75	23	3030	146	42618136
Hepatic artery stenosis	149.04	24.75	23	3030	159	42618123
Contrast media allergy	121.44	24.75	24	3029	763	42617519
Urticaria	84.10	24.75	57	2996	73979	42544303
Extravasation	61.39	24.75	17	3036	2373	42615909
Hepatic artery occlusion	47.77	24.75	8	3045	97	42618185
Cardio-respiratory arrest	45.71	24.75	36	3017	58600	42559682
Kounis syndrome	43.13	24.75	14	3039	3354	42614928
Pruritus	41.79	24.75	59	2994	188712	42429570
No adverse event	39.42	24.75	28	3025	38993	42579289
Cardiac arrest	36.57	24.75	42	3011	109278	42509004
Blood pressure decreased	35.42	24.75	31	3022	58301	42559981
Drug reaction with eosinophilia and systemic symptoms	35.31	24.75	27	3026	42048	42576234
Hypersensitivity	31.55	24.75	32	3021	72338	42545944
Sialoadenitis	31.43	24.75	8	3045	807	42617475
Unresponsive to stimuli	30.48	24.75	22	3031	31381	42586901
Vomiting	29.14	24.75	64	2989	289659	42328623
Oxygen saturation decreased	28.92	24.75	29	3024	64658	42553624
Throat irritation	24.87	24.75	14	3039	13022	42605260

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	585.39	23.93	104	6296	2294	110580605
Anaphylactic shock	372.55	23.93	132	6268	51414	110531485
Anaphylactic reaction	335.90	23.93	153	6247	114147	110468752
Contrast encephalopathy	298.01	23.93	45	6355	337	110582562
Hepatic artery stenosis	172.42	23.93	27	6373	263	110582636
Contrast media allergy	162.06	23.93	38	6362	3385	110579514
Urticaria	133.48	23.93	125	6275	318732	110264167
Drug reaction with eosinophilia and systemic symptoms	115.36	23.93	67	6333	82028	110500871
Cardio-respiratory arrest	94.23	23.93	67	6333	115769	110467130
Sialoadenitis	92.24	23.93	23	6377	2650	110580249
Sneezing	84.89	23.93	40	6360	31944	110550955
Extravasation	83.12	23.93	24	6376	4821	110578078
Throat irritation	75.97	23.93	44	6356	53508	110529391
Throat tightness	74.16	23.93	37	6363	33452	110549447
Pruritus	68.09	23.93	121	6279	581439	110001460
Cardiac arrest	65.16	23.93	68	6332	196685	110386214
Pulse absent	63.18	23.93	24	6376	11268	110571631
Anaphylactoid reaction	62.87	23.93	21	6379	6805	110576094
Unresponsive to stimuli	61.51	23.93	41	6359	63749	110519150
Erythema	52.55	23.93	74	6326	291373	110291526
Hypersensitivity	52.35	23.93	88	6312	403910	110178989
Dyspnoea	50.32	23.93	159	6241	1106713	109476186
Kounis syndrome	49.73	23.93	17	6383	5908	110576991
Blood pressure decreased	49.67	23.93	46	6354	115045	110467854
Hepatic artery occlusion	48.75	23.93	8	6392	107	110582792
Oxygen saturation decreased	47.95	23.93	52	6348	156930	110425969
Nephropathy toxic	42.77	23.93	24	6376	27454	110555445
Rapidly progressive osteoarthritis	41.17	23.93	6	6394	34	110582865
Loss of consciousness	40.12	23.93	53	6347	196253	110386646
Cyanosis	38.38	23.93	23	6377	29718	110553181
No adverse event	36.76	23.93	32	6368	73807	110509092
Product physical issue	36.68	23.93	13	6387	5023	110577876
Pharyngeal oedema	35.91	23.93	18	6382	16410	110566489
Vomiting	35.20	23.93	124	6276	910551	109672348
Flushing	34.27	23.93	36	6364	104700	110478199
Foaming at mouth	33.46	23.93	10	6390	2260	110580639
Respiratory arrest	32.57	23.93	27	6373	58272	110524627
Acute kidney injury	32.21	23.93	95	6305	635335	109947564
Chest discomfort	31.08	23.93	44	6356	173804	110409095
Drug ineffective	28.22	23.93	28	6372	1520512	109062387
Nausea	27.31	23.93	142	6258	1235548	109347351
Angioedema	27.25	23.93	31	6369	98469	110484430
Wrong product administered	26.91	23.93	13	6387	10947	110571952
Infusion site extravasation	26.17	23.93	13	6387	11621	110571278
Documented hypersensitivity to administered product	25.76	23.93	7	6393	1127	110581772
Blood pressure immeasurable	24.50	23.93	8	6392	2415	110580484
Spinal cord ischaemia	24.36	23.93	5	6395	239	110582660
Aphasia	24.32	23.93	23	6377	58974	110523925
Product deposit	23.99	23.93	6	6394	699	110582200

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB04	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
FDA EPC	N0000180185	Radiographic Contrast Agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:37338	radioopaque medium
CHEBI has role	CHEBI:78298	environmental contaminant

Related Drugs by ATC class:

V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs

iobitridol iodixanol iohexol iomeprol iopentol iopromide iotrolan ioversol ioxaglic acid ioxilan metrizamide

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.76	acidic
pKa2	11.36	acidic
pKa3	12.12	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
41%	ISOVUE-200	BRACCO	N018735	July 7, 1987	RX	INJECTABLE	INJECTION	Oct. 10, 2028	FOR ORAL ADMINISTRATION TO DELINEATE THE GASTROINTESTINAL TRACT ON COMPUTED TOMOGRAPHY OF THE ABDOMEN AND PELVIS IN ADULT AND PEDIATRIC PATIENTS
51%	ISOVUE-250	BRACCO	N018735	July 6, 1992	RX	INJECTABLE	INJECTION	Oct. 10, 2028	FOR ORAL ADMINISTRATION TO DELINEATE THE GASTROINTESTINAL TRACT ON COMPUTED TOMOGRAPHY OF THE ABDOMEN AND PELVIS IN ADULT AND PEDIATRIC PATIENTS
61%	ISOVUE-300	BRACCO	N018735	Dec. 31, 1985	RX	INJECTABLE	INJECTION	Oct. 10, 2028	FOR ORAL ADMINISTRATION TO DELINEATE THE GASTROINTESTINAL TRACT ON COMPUTED TOMOGRAPHY OF THE ABDOMEN AND PELVIS IN ADULT AND PEDIATRIC PATIENTS
76%	ISOVUE-370	BRACCO	N018735	Dec. 31, 1985	RX	INJECTABLE	INJECTION	Oct. 10, 2028	FOR ORAL ADMINISTRATION TO DELINEATE THE GASTROINTESTINAL TRACT ON COMPUTED TOMOGRAPHY OF THE ABDOMEN AND PELVIS IN ADULT AND PEDIATRIC PATIENTS

Bioactivity Summary:

None

External reference:

ID	Source
4017756	VUID
N0000146122	NUI
D01797	KEGG_DRUG
4017756	VANDF
C0022026	UMLSCUI
CHEBI:31711	CHEBI
CHEMBL1200932	ChEMBL_ID
D007479	MESH_DESCRIPTOR_UI
DB08947	DRUGBANK_ID
4399	INN_ID
JR13W81H44	UNII
65492	PUBCHEM_CID
5966	RXNORM
206534	MMSL
4905	MMSL
d01461	MMSL
000672	NDDF
109219007	SNOMEDCT_US
395754005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ISOVUE200	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1314	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE200	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1314	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE300	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1315	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE300	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1315	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE300	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1315	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE370	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1316	INJECTION, SOLUTION	755 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE370	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1316	INJECTION, SOLUTION	755 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE370	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1316	INJECTION, SOLUTION	755 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE250	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1317	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE250	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1317	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	NDA	21 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1411	INJECTION, SOLUTION	408 mg	INTRATHECAL	NDA	17 sections
ISOVUE-M	HUMAN PRESCRIPTION DRUG LABEL	1	0270-1412	INJECTION, SOLUTION	612 mg	INTRATHECAL	NDA	17 sections
ISOVUE-M 200	HUMAN PRESCRIPTION DRUG LABEL	1	52584-411	INJECTION, SOLUTION	408 mg	INTRATHECAL	NDA	11 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-124	INJECTION, SOLUTION	408 mg	INTRATHECAL	ANDA	21 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-125	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	ANDA	27 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-126	INJECTION, SOLUTION	612 mg	INTRATHECAL	ANDA	21 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-127	INJECTION, SOLUTION	755 mg	INTRAVASCULAR	ANDA	27 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-211	INJECTION, SOLUTION	408 mg	INTRAVASCULAR	ANDA	27 sections
iopamidol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-219	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	ANDA	27 sections

Ask DrugCentral

Try a sample question

iopamidol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: